Celcuity
Celcuity

Celcuity

Biotechnology
WebsiteInvestor RelationsSEC
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company’s lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

$3.3B

Market Cap • 10/9/2026

2011

(15 years)

Founded

2017

(9 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

—

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

—

EPS

—

Market Cap

Market Cap

3,3B

EV

3,3B

EV/Revenue

0

EV/EBITDA

-15,9

EV/EBIT

-15,9

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-4,1%

Total Yield

-4,1%

Payout

0%

Retained Earnings

-580,6M

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

229,6%

Capex/OCF

-0,2%

SBC/OCF

—

% PPE

0,2%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Op. Income 5Y

57,6%

CAGR Net Income 5Y

59,6%

CAGR EPS 5Y

18,4%

CAGR OCF 5Y

69%

Leverage

N.D./EBITDA

—

Debt/Equity

0%

Current Ratio

8,9

Quick Ratio

8,7

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium